Shared immune and repair markers during experimental toxoplasma chronic brain infection and schizophrenia

Schizophrenia Bulletin

Volumn 42, Issue 2, 2016, Pages 386-395

  Tomasik, Jakub ^a,b   Schultz, Tracey L ^c   Kluge, Wolfgang ^a   Yolken, Robert H ^d   Bahn, Sabine ^a,b   Carruthers, Vern B ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Biomarker; Toxoplasma gondii

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFECTION; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; TISSUE REPAIR; TOXOPLASMOSIS; ANIMAL; BRAIN; CEREBRAL TOXOPLASMOSIS; CHRONIC DISEASE; DISEASE MODEL; IMMUNOLOGY; METABOLISM; PATHOGENICITY; TOXOPLASMA;

ANIMALS; BIOMARKERS; BRAIN; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS; MICE; SCHIZOPHRENIA; TOXOPLASMA; TOXOPLASMOSIS, CEREBRAL;

EID: 84964866776     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv134     Document Type: Article

References (59)

1. Mortensen PB, Pedersen CB, Westergaard T, et al. Effects of family history and place and season of birth on the risk of schizophrenia. N Engl J Med. 1999;340:603-608.
2. Giusti-Rodriguez P, Sullivan PF. The genomics of schizophrenia: update and implications. J Clin Invest. 2013;123:4557-4563.
3. Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci. 2015;18:199-209.
4. Anders S, Kinney DK. Abnormal immune system development and function in schizophrenia helps reconcile diverse findings and suggests new treatment and prevention strategies. Brain Res. 2015;1617:93-112.
5. Arias I, Sorlozano A, Villegas E, et al. Infectious agents associated with schizophrenia: A meta- Analysis. Schizophr Res. 2012;136:128-136.
6. Torrey EF, Bartko JJ, Yolken RH. Toxoplasma gondii and other risk factors for schizophrenia: An update. Schizophr Bull. 2012;38:642-647.
7. Thompson RC. Parasite zoonoses and wildlife: One Health, spillover and human activity. Int J Parasitol. 2013;43:1079-1088.
8. Myint AM. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 2012;279:1375-1385.
9. Kegel ME, Bhat M, Skogh E, et al. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res. 2014;7:15-22.
10. Notarangelo FM, Wilson EH, Horning KJ, et al. Evaluation of kynurenine pathway metabolism in Toxoplasma gondiiinfected mice: implications for schizophrenia. Schizophr Res. 2014;152:261-267.
11. Hermes G, Ajioka JW, Kelly KA, et al. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation. 2008;5:48.
12. Torres M, Guiton R, Lacroix-Lamandé S, Ryffel B, Leman S, Dimier-Poisson I. MyD88 is crucial for the development of a protective CNS immune response to Toxoplasma gondii infection. J Neuroinflammation. 2013;10:19.
13. Catts VS, Wong J, Fillman SG, Fung SJ, Shannon Weickert C. Increased expression of astrocyte markers in schizophrenia: Association with neuroinflammation. Aust N Z J Psychiatry. 2014;48:722-734.
14. Debnath M, Berk M. Th17 pathway-mediated immunopathogenesis of schizophrenia: mechanisms and implications. Schizophr Bull. 2014;40:1412-1421.
15. Hayes LN, Severance EG, Leek JT, et al. Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr Bull. 2014;40:963-972.
16. Singh B, Chaudhuri TK. Role of C-reactive protein in schizophrenia: An overview. Psychiatry Res. 2014;216:277-285.
17. Stojanovic A, Martorell L, Montalvo I, et al. Increased serum interleukin-6 levels in early stages of psychosis: Associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology. 2014;41:23-32.
18. Xiao J, Li Y, Jones-Brando L, Yolken RH. Abnormalities of neurotransmitter and neuropeptide systems in human neuroepithelioma cells infected by three Toxoplasma strains. J Neural Transm. 2013;120:1631-1639.
19. Amato D. Serotonin in antipsychotic drugs action. Behav Brain Res. 2015;277:125-135.
20. Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: An update for the 21st century. J Psychopharmacol. 2015;29:97-115.
21. Parlog A, Schlüter D, Dunay IR. Toxoplasma gondii-induced neuronal alterations. Parasite Immunol. 2015;37:159-170.
22. Parlog A, Harsan LA, Zagrebelsky M, et al. Chronic murine toxoplasmosis is defined by subtle changes in neuronal connectivity. Dis Model Mech. 2014;7:459-469.
23. Berdoy M, Webster JP, Macdonald DW. Fatal attraction in rats infected with Toxoplasma gondii. Proc Biol Sci. 2000;267:1591-1594.
24. Vyas A, Kim SK, Giacomini N, Boothroyd JC, Sapolsky RM. Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proc Natl Acad Sci U S A. 2007;104:6442-6447.
25. Flegr J. How and why Toxoplasma makes us crazy. Trends Parasitol. 2013;29:156-163.
26. Wang HL, Wang GH, Li QY, Shu C, Jiang MS, Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand. 2006;114:40-48.
27. Holub D, Flegr J, Dragomirecká E, et al. Differences in onset of disease and severity of psychopathology between toxoplasmosis- related and toxoplasmosis-unrelated schizophrenia. Acta Psychiatr Scand. 2013;127:227-238.
28. Horacek J, Flegr J, Tintera J, et al. Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: voxel-based-morphometry (VBM) study. World J Biol Psychiatry. 2012;13:501-509.
29. Schultz TL, Hencken CP, Woodard LE, et al. A thiazole derivative of artemisinin moderately reduces Toxoplasma gondii cyst burden in infected mice. J Parasitol. 2014;100:516-521.
30. Schwarz E, Izmailov R, Spain M, et al. Validation of a bloodbased laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights. 2010;5:39-47.
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B. 1995;51:289-300.
32. Harris LW, Pietsch S, Cheng TM, Schwarz E, Guest PC, Bahn S. Comparison of peripheral and central schizophrenia biomarker profiles. PLoS One. 2012;7:e46368.
33. Tanaka S, Nishimura M, Ihara F, Yamagishi J, Suzuki Y, Nishikawa Y. Transcriptome analysis of mouse brain infected with Toxoplasma gondii. Infect Immun. 2013;81:3609-3619.
34. Pittman KJ, Aliota MT, Knoll LJ. Dual transcriptional profiling of mice and Toxoplasma gondii during acute and chronic infection. BMC Genomics. 2014;15:806.
35. Singh J, Graniello C, Ni Y, et al. Toxoplasma IgG and IgA, but not IgM, antibody titers increase in sera of immunocompetent mice in association with proliferation of tachyzoites in the brain during the chronic stage of infection. Microbes Infect. 2010;12:1252-1257.
36. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest. 2003;111:1805-1812.
37. Brinkmann V, Remington JS, Sharma SD. Protective immunity in toxoplasmosis: correlation between antibody response, brain cyst formation, T-cell activation, and survival in normal and B-cell-deficient mice bearing the H-2k haplotype. Infect Immun. 1987;55:990-994.
38. Suzuki Y, Joh K, Orellana MA, Conley FK, Remington JS. A gene(s) within the H-2D region determines the development of toxoplasmic encephalitis in mice. Immunology. 1991;74:732-739.
39. Suzuki Y, Claflin J, Wang X, Lengi A, Kikuchi T. Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplasma gondii. Int J Parasitol. 2005;35:83-90.
40. Yap GS, Sher A. Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. Immunobiology. 1999;201:240-247.
41. Taylor MW, Feng GS. Relationship between interferongamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5:2516-2522.
42. Benjamins JA, Nedelkoska L, Lisak RP. Adrenocorticotropin hormone 1-39 promotes proliferation and differentiation of oligodendroglial progenitor cells and protects from excitotoxic and inflammation-related damage. J Neurosci Res. 2014;92:1243-1251.
43. Wang X, Michie SA, Xu B, Suzuki Y. Importance of IFNgamma- mediated expression of endothelial VCAM-1 on recruitment of CD8+ T cells into the brain during chronic infection with Toxoplasma gondii. J Interferon Cytokine Res. 2007;27:329-338.
44. Wilson EH, Harris TH, Mrass P, et al. Behavior of parasitespecific effector CD8+ T cells in the brain and visualization of a kinesis- Associated system of reticular fibers. Immunity. 2009;30:300-311.
45. Fabiani S, Pinto B, Bonuccelli U, Bruschi F. Neurobiological studies on the relationship between toxoplasmosis and neuropsychiatric diseases. J Neurol Sci. 2015;351:3-8.
46. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999;122:593-624.
47. Flynn SW, Lang DJ, Mackay AL, et al. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry. 2003;8:811-820.
48. Dickerson F, Stallings C, Origoni A, et al. C-reactive protein is elevated in schizophrenia. Schizophr Res. 2013;143:198-202.
49. Hinze-Selch D, Däubener W, Eggert L, Erdag S, Stoltenberg R, Wilms S. A controlled prospective study of toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence. Schizophr Bull. 2007;33:782-788.
50. Suvisaari J, Loo BM, Saarni SE, et al. Inflammation in psychotic disorders: A population-based study. Psychiatry Res. 2011;189:305-311.
51. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93:261-265.
52. Clark RT, Nance JP, Noor S, Wilson EH. T-cell production of matrix metalloproteinases and inhibition of parasite clearance by TIMP-1 during chronic Toxoplasma infection in the brain. ASN Neuro. 2011;3:e00049.
53. Okulski P, Jay TM, Jaworski J, et al. TIMP-1 abolishes MMP- 9-dependent long-lasting long- Term potentiation in the prefrontal cortex. Biol Psychiatry. 2007;62:359-362.
54. Hasan A, Nitsche MA, Rein B, et al. Dysfunctional longterm potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav Brain Res. 2011;224:15-22.
55. Berretta S. Extracellular matrix abnormalities in schizophrenia. Neuropharmacology. 2012;62:1584-1597.
56. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol. 2012;227:493-507.
57. Mou X, Peterson CB, Prosser RA. Tissue- Type plasminogen activator-plasmin-BDNF modulate glutamate-induced phase-shifts of the mouse suprachiasmatic circadian clock in vitro. Eur J Neurosci. 2009;30:1451-1460.
58. Yolken R. Viruses and schizophrenia: A focus on herpes simplex virus. Herpes. 2004;11:83A-88A.
59. Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB. Childhood infection and adult schizophrenia: A metaanalysis of population-based studies. Schizophr Res. 2012;139:161-168.